Cost-Effectiveness and Cost-Utility Analysis of Cinnarizine Compared to Valproate in Pediatric Migraine: An Iranian Perspective
Iranian Journal of Child Neurology,
Vol. 20 No. 3 (2026),
1 June 2026
,
Page 45-54
https://doi.org/10.22037/ijcn.v20i3.50463
Abstract
Objectives: Childhood migraine is a prevalent neurovascular disease in children with a considerable reduction in quality of life and high social cost. Anticonvulsants, such as Valproate and calcium channel blockers, including Cinnarizine are used frequently as preventive medications. This research evaluates the cost-effectiveness and cost-utility of Cinnarizine versus Valproate in managing childhood migraine, based on an Iranian societal perspective.
Materials & Methods:
A randomized cohort trial was conducted, involving 150 children aged 5 to 17 years at the Imam Reza Clinic in Shiraz, Iran. Patients were administered Cinnarizine (1–2 mg/kg/day) or Valproate (10–20 mg/kg/day) for three months, evaluated by decision-tree models for cost-utility and cost-effectiveness. Effectiveness was measured by reduction in migraine attack frequency and Quality-Adjusted Life Years (QALYs). Costs were obtained from patient medical records, questionnaires, and national datasets, including direct and indirect costs. Sensitivity analysis, such as Monte Carlo simulations, was performed to validate the results.
Results:
Patients receiving Cinnarizine experienced a mean QALYs of 0.213 versus 0.209 for the Valproate group and a higher rate of response at 26% (Cinnarizine) versus 14% (Valproate). Total costs during the study period favored Cinnarizine ($183 vs. $191) with an Incremental Cost Effectiveness Ratio of $-156 per additional effect and an Incremental Cost Utility Ratio of $-2069 per QALYs. Adverse effects noted were drowsiness (17.8%) for the Cinnarizine and dizziness (13.5%) for the Valproate arm. Probabilistic sensitivity analysis contained an 88.2% probability that Cinnarizine was cost-effective with a willingness-to-pay of $17,922 per QALYs.
Conclusion:
Cinnarizine was a cheaper option compared to Valproate as a prophylactic agent in pediatric migraine in Iran with higher response rates, lower expenses, and similar effectiveness. Further research with long-term follow-ups and varied populations is needed to validate the results
- cost effectiveness, cinnarizine, valproate, childhood, migraine
How to Cite
References
Gilmore, B. and M. Michael, Treatment of acute migraine headache. American family physician, 2011. 83(3): p. 271-280.
Arnold, M., Headache classification committee of the international headache society (IHS) the international classification of headache disorders. Cephalalgia, 2018. 38(1): p. 1-211.
Ailani, J., et al., The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain, 2021. 61(7): p. 1021-1039.
Nieswand, V., M. Richter, and G. Gossrau, Epidemiology of headache in children and adolescents—another type of pandemia. Current Pain and Headache Reports, 2020. 24: p. 1-10.
Powers, S.W., et al., Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses. Pediatrics, 2003. 112(1): p. e1-e5.
Sadeghi, O., M. Nasiri, and S.G. Saiedi, The prevalence of migraine in different parts of Iran: review of the current evidence. Jundishapur Journal of Chronic Disease Care, 2015. 4(3).
Bahrami, P., et al., Prevalence and characteristics of headache in Khoramabad, Iran. Pain physician, 2012. 15(4): p. 327.
Ayatollahi, S. and A. Khosravi, Prevalence of migraine and tension-type headache in primary-school children in Shiraz. EMHJ-Eastern Mediterranean Health Journal, 12 (6), 809-817, 2006, 2006.
Farhadi, Z., et al., The prevalence of migraine in Iran: a systematic review and meta-analysis. Iranian Red Crescent Medical Journal, 2016. 18(10).
Arruda, M.A. and M.E. Bigal, Migraine and migraine subtypes in preadolescent children: association with school performance. Neurology, 2012. 79(18): p. 1881-1888.
Buse, D.C., et al., Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia, 2018. 38(10): p. 1622-1631.
Mansoureh, T., et al., Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate. The journal of headache and pain, 2008. 9: p. 77-82.
Shafie'ei, M., et al., Application of cinnarizine in migraine prevention: A systematic review and meta‐analysis. Pain Practice, 2022. 22(8): p. 733-745.
Khrizman, M. and A. Pakalnis, Management of pediatric migraine: current therapies. Pediatric Annals, 2018. 47(2): p. e55-e60.
Gibler, R.C., et al., Management of chronic migraine in children and adolescents: where are we in 2022? Pediatric health, medicine and therapeutics, 2022: p. 309-323.
Gargari, O.K., et al., Preventive Medications in Pediatric Migraine: A Network Meta-Analysis. JAMA Network Open, 2024. 7(10): p. e2438666-e2438666.
Ichikawa, M., et al., Clinical response to valproate in patients with migraine. Journal of Clinical Neurology, 2016. 12(4): p. 468-475.
Hering, R., Migraine and antiphospholipid antibodies. Cephalalgia: an International Journal of Headache, 1992. 12(2): p. 67-67.
Arab, S.F., et al., Inhibition of voltage-gated calcium currents in type II vestibular hair cells by cinnarizine. Naunyn-Schmiedeberg's archives of pharmacology, 2004. 369: p. 570-575.
Amanat, M., et al., Cinnarizine and sodium valproate as the preventive agents of pediatric migraine: A randomized double-blind placebo-controlled trial. Cephalalgia, 2020. 40(7): p. 665-674.
Trading Economics. GDP per capita, P.c.i.i.I., Available from: https://tradingeconomics.com/iran/gdp-per-capita-ppp-us-dollar-wb-data.html#:~:text=GDP%20per%20capita%2C%20PPP%20(current%20international%20%24)%20in%20Iran%20was,compiled%20from%20officially%20recognized%20sources. 2024.
Bank., W., GDP per capita, PPP (current international $). Available from: https://wdi.worldbank.org/table/4.16. 2024.
Bostani, A., et al., The effects of cinnarizine versus sodium valproate in migraine prophylaxis. International Journal of Neuroscience, 2013. 123(7): p. 487-493.
- Abstract Viewed: 2 times